Dr. Paul Humphries joined Stanford in 2018 as the Alliance Director of the Stanford Alliance for Innovative Medicines (AIM). Dr. Humphries provides strategic leadership and management of the Stanford AIM program to accelerate the translation of Stanford research into next-generation treatments that impact human health. Dr. Humphries comes to ChEM-H with over 19 years of research and development experience, including leadership of target-based and phenotypic drug discovery programs ranging from target/phenotype identification to Phase 2 clinical trials. He has advanced eight compounds into the clinic. Prior to joining ChEM-H, Dr. Humphries worked as Chief Scientific Officer for Reset Therapeutics where he assumed full responsibility for all aspects of research and nonclinical development and focused on harnessing the power of the body’s internal molecular clocks to discover, develop, and commercialize high-value therapeutics for a variety of disease indications. Prior to this, Dr. Humphries worked at Pfizer on numerous drug discovery programs resulting in seven IND submissions across four late-stage projects and was responsible for numerous go/no go decisions on early stage projects. He has authored approximately 30 scientific articles and patents on a wide range of topics/drug targets. Dr. Humphries received his Ph.D. in organic chemistry from the University of Sheffield, UK and conducted post-doctoral research at Florida State University.